# Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

> **NCT05049122** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 25 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** Dupilumab SAR231893

## Key facts

- **NCT ID:** NCT05049122
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-22
- **Primary completion:** 2022-12-21
- **Final completion:** 2023-07-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049122, "Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05049122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*